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consumables amount 0.84€ per preparation (0.48€ due to time
saving and 0.36€ linked to less use of consumables). For the case
of colorectal cancer standard chemotherapy regimen in adjuvant
(12 cycles) these savings could mean annually 10,080€ per 1,000
patients. CONCLUSION: The concentration solution, a new
presentation of oxaliplatin, has signiﬁcant advantages compared
with the traditional lyophilised powder. These advantages have
been measured as monetary savings linked to less preparation
time and use of consumables. In the future it would be of interest
to assess other advantages of concentrated solution chemothera-
pies over the more conventional ones like less errors of medica-
tion due to manipulation.
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OBJECTIVES: A recent randomized 2 ¥ 2 phase III trial com-
pared oral capecitabine + IV oxaliplatin (XELOX), IV 5-FU/LV/
oxaliplatin (FOLFOX-4), XELOX+bev, and FOLFOX-4+bev as
ﬁrst-line therapy for MCRC. FOLFOX-4 was the regulatory
control. XELOX was non-inferior to FOLFOX-4 for
progression-free survival, and bev-containing regimens were
superior to comparison arms. This economic analysis compared
expected costs in XELOX vs. FOLFOX-4 arms in an Italian
hospital setting from a payer and societal perspective.
METHODS: Direct medical and indirect cost estimates (for
patient time and travel) were compared. Resource use and
patient time were estimated based on trial data and protocols.
Data collected during the trial and used in the analysis were as
follows: no. of visits/duration of drug administration, central
venous access management, treatment of adverse events (AE)
including hospital days for treatment-related AEs and total hours
of ambulatory encounters. Unit costs were based on hospital
costs and other published sources. RESULTS: Total direct
medical cost estimates were higher for bi-weekly FOLFOX-4 vs.
3-weekly XELOX: €17,900 vs. €10,900. XELOX had higher
drug costs while FOLFOX-4 had higher drug administration
costs, with about 15 more visits on average per patient. Costs for
hospitalization and ambulatory encounters were slightly lower
for FOLFOX-4 (€500 vs. €800); other medications and venous
access were slightly higher for FOLFOX-4 (€5000 vs. €2000).
Similar patterns held for FOLFOX-4+bev vs. XELOX+bev (total
direct medical cost estimates €33,100 vs. €25,000). Indirect time
cost estimates were lower with XELOX due to fewer cycles and
visits: estimated savings range from €9,000–€11,000. CONCLU-
SION: XELOX is cost-saving from both payer and societal per-
spective in comparison to FOLFOX-4.
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OBJECTIVES: The objective of this study was to estimate Irish
speciﬁc costs for managing abnormal cervical conditions which
are required for cost-effectiveness analysis of prophylactic cervi-
cal cancer vaccination in Ireland. Methods: This was a retrospec-
tive study that collected resource utilisation and clinical outcome
data on 395 women attending four colposcopy clinics in Ireland.
Sampling was stratiﬁed to include 10%, 35%, 25%, 25% and
5% of women in the borderline, mild, moderate, severe and
cancer cytology groups respectively. Data were collected from the
date of referral until the latest treatment or the patient returned
to ‘normal’ cytology. Unit cost data, also collected during the
study, were applied to the utilisation data to estimate costs.
RESULTS: The mean age of all women with abnormal smears
was 31 years (range 18–68). The mean age of women with cancer
was 48 (range 23–68). The average cost of treating women who
initially had an abnormal smear but were subsequently observed
to be histologically negative without receiving treatment was
€317 (SD €147). The corresponding costs for women with CIN1,
CIN2 and CIN3 were €522 (SD €255), €673 (SD €237), and
€689 (SD €227) respectively. The average cost of treating invasive
cervical cancer was €10,449 (SD €4,952). The total cost of man-
aging abnormal cervical conditions was estimated at around €10
million per annum. CONCLUSION: Managing abnormal cervi-
cal conditions is expensive. Analysis in other countries found that
prophylactic cervical cancer vaccination is a cost effective way to
reduce these abnormalities [1]. This study will be used in a cost
effectiveness analysis of prophylactic cervical cancer vaccination
in Ireland. Reference: [1] Goldie SJ, et al. J Natl Cancer Inst
2004;96:604–15.
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OBJECTIVES: The purpose of this study was to estimate the
budget impact on the German health care service of using Hexvix
(hexaminolevulinate) cystoscopy in conjunction with white light
cystoscopy (WLC) in the management of non-invasive bladder
cancer (NIBC). Hexvix cystoscopy potentially allows more com-
plete detection and delineation of bladder cancer tumours com-
pared with standard WLC alone during transurethral resection of
the bladder (TURB). This can potentially lead to fewer tumour
recurrences through more effective tumour resection, and may
change patient management. METHODS: A model was devel-
oped to simulate the ﬂow of newly diagnosed bladder cancer
patients through treatment one year after diagnosis. Model
inputs, including procedure costs and clinical algorithms, are
based on the bladder cancer guidelines by the European Associa-
tion of Urology (EAU), literature review and German clinical
practice. Based on data obtained with an unlicensed and less
readily taken up ﬂuorescent molecule, a relative reduction in
recurrence rate is assumed in the model when compared to WLC.
RESULTS: The model predicts that Hexvix is associated with a
potential reduction in the number of procedures required com-
pared to WLC alone (801 cystectomies and 31,734 TURBs with
Hexvix compared to 881 and 33,823 with WLC alone) in the
ﬁrst year. This is estimated to result in a potential increase in
costs to the German health care system of 5.76% in the ﬁrst year,
compared to WLC alone in all newly diagnosed NIBC patients.
CONCLUSION: The model illustrates how Hexvix, when used
as an adjunct to WLC in TURB may result in the reduction of
invasive, time intensive, high cost procedures such as cystecto-
mies and TURBs, compared with WLC alone. Although the
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model predicts an increase in cost for the German health care
system in the ﬁrst year model does not take into account
improvements in quality of life.
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OBJECTIVES: Approximately 80% of newly diagnosed bladder
cancer patients in the UK will be diagnosed with non-invasive
bladder cancer (NIBC). The use of Hexvix (hexaminolevulinate)
during transurethral resection of the bladder (TURB) results in a
higher detection rate and more complete resection when com-
pared to white light cystoscopy (WLC) alone. A decision tree
model was developed to assess the budget impact associated with
Hexvix. METHODS: The model structure, costs and treatment
algorithms were based on the European Association of Urologist
(EAU) guidelines, review of the literature and clinical practice in
the UK. The model assumes a relative reduction in recurrence for
Hexvix when compared to WLC based on data obtained with an
unlicensed and less readily taken up ﬂuorescent molecule. Model
predictions include cost savings, reductions in procedures and
disease-free days (DFD) over a two year time horizon. RESULTS:
Of the 12,000 patients diagnosed with bladder cancer in the UK,
9641 were predicted by the model to have NIBC. In these
patients, the model predicts an 18% reduction in the number of
cystoscopies and 4.3% reduction in TURBs when Hexvix use
was compared to WLC. In addition, an increase of 211 106 DFD
was predicted over the 2 year time horizon (177,029 in 2410
high risk patients, 14,721 in 2410 medium risk patients and
19,355 in 4821 low risk patients). The model predicts an overall
increase in cost of managing these patients of 2,769,712
(3.9%) over WLC, and an incremental cost of 21.90 per
patient per disease-free year. CONCLUSION: Although the
quality of life was not modelled the assumed reduction in the
number of cystoscopies and TURBS could potentially have a
signiﬁcant impact on the quality of life. The increase in the cost
of may be off-set by the improvement to the current regimen.
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OBJECTIVES: To analyse resource use and direct medical cost of
sepsis as adverse drug reaction of cancer treatment. Special
regard was paid to the use of blood products. METHODS:
Prospective observational study in a German academic cancer
center (ACC). Consecutive non-small cell lung cancer (NSCLC)
and lymphoma patients were enrolled at the start of ﬁrst or
second line (immuno) chemotherapy treatment. Patients receiv-
ing high dose chemotherapy were excluded. Sepsis (infection
grade 4) was recorded prospectively according to the Common
Terminology Criteria for Adverse Events v3.0. Clinical data and
resource use at the ACC were collected from pre-planned chart
reviews. Direct costs were calculated from ACC perspective.
RESULTS: In all, 180 evaluable patients underwent a total of
633 chemotherapy cycles. Seven episodes of sepsis were observed
in 7 patients (3.9%). Five of them had malignant lymphoma.
Three patients received sepsis treatment at a local hospital and 4
at the ACC. All ACC patients received intravenous antibiotics
and diagnostic work-up for infection. Blood components were
transfused to 3 patients. Median and range of the number of
transfusion units per patient were 6 (4–17), 14 (4–24), 23.5
(14–33) and 24 (4–74) for red blood cells, platelets, fresh frozen
plasma and all blood components respectively. 3 of 4 patients
were treated at an intensive care unit (ICU) for 9–31 days.
Overall median length of stay was 18.5 days. Total cost per
episode varied between €8.077 and €67.437. In all episodes basic
hotel services and personnel costs were the cost driver (€3.795–
35.898), followed by expenses for drugs (€1.489–9.151) and
blood products (€0–10.976). CONCLUSION: Health care utili-
sation and cost of treating one episode of sepsis varied substan-
tially. Transfusion need was heterogeneous but high on average.
Further research should compare costs and revenue of high-
cost-cases in the German DRG system.
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OBJECTIVES: Breast cancer often metastasizes to the bone,
which leads to poor quality of life for the patients. Many
patients with bone metastases are currently treated with bis-
phosphonates. There are different molecules and formulations
of bisphosphonates available. Intravenous (IV) administration
is associated with more resource utilization and higher cost
than oral administration due to use of hospital facilities, equip-
ments and increased pharmacy and nurse time for preparing
and administrating the drug. The objective of this study was to
estimate resource use and perform a microcosting analysis of
bisphosphonate administration in the treatment of metastatic
bone disease in Swedish breast cancer patients. METHODS: A
sample of patients receiving IV administration of bisphospho-
nate was identiﬁed at two hospitals in Stockholm and Uppsala,
Sweden. All patients had breast cancer with bone metastasis.
Resources associated with IV administration were identiﬁed
and the utilization estimated. The resource use attributable to
the bisphosphonate administration during each patient visit was
recorded in a data collection form speciﬁcally developed for the
study. RESULTS: The 26 patients included in the study all
received either ibandronate or zoledronic acid. The cost analy-
sis showed that the mean cost of bisphosphonate administra-
tion to breast cancer patients was €94. Of this, 84%
constituted direct costs and 16% indirect costs. The patients
spent on average 76 minutes at the clinic and the administra-
tion took on average 16 minutes. Nursing time and cost of
facilities were the greatest direct cost drivers. CONCLUSION:
The patients included in the study all received bisphosphonates
requiring short infusion times. The administration is associated
with costs, which should be taken into account in the choice of
bisphosphonate treatment. Bisphosphonates requiring longer
infusion time than the drugs included in this study would be
associated with higher costs. The incremental cost per addi-
tional infusion hour was estimate to about €33.
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